Roche’s Actemra Gets FDA Panel Vote Of Confidence With Robust P-vigilance
This article was originally published in The Pink Sheet Daily
Executive Summary
Arthritis Drugs Advisory Committee selects more cautious starting dose for Roche’s rheumatoid arthritis therapy during July 29 meeting.
You may also be interested in...
Roche's Actemra Approved For RA After Year's Delay - To Craft A REMS?
Roche's novel interleukin-6 inhibitor Actemra won FDA approval Jan. 8 for second-line use in rheumatoid arthritis - after an FDA "complete response" letter set the product's regulatory process back more than a year
Roche's Actemra Approved For RA After Year's Delay - To Craft A REMS?
Roche's novel interleukin-6 inhibitor Actemra won FDA approval Jan. 8 for second-line use in rheumatoid arthritis - after an FDA "complete response" letter set the product's regulatory process back more than a year
Roche’s Actemra Delayed By REMS, FDA Study Requirements
Roche expects to submit a complete response to FDA for the first-in-class IL-6 inhibitor for rheumatoid arthritis in the third quarter next year.